Neuroblastoma pp 267-276 | Cite as

Experimental Therapeutics and Preclinical Models

  • Jennifer K. Peterson
  • Peter J. Houghton
Part of the Pediatric Oncology book series (PEDIATRICO)


Newcastle Disease Virus Murine Neuroblastoma Syngeneic Model Neuroblastoma Xenograft Human Neuroblastoma Xenograft 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Backman U, Svensson A, Christofferson R (2002) Importance of vascular endothelial growth factor A in the progression of experimental neuroblastoma. Angiogenesis 5:267–274CrossRefPubMedGoogle Scholar
  2. Bergman I, Barmada MA, Heller G, Griffin JA, Cheung NK (1999) Treatment of neoplastic meningeal xenografts by intraventricular administration of an antiganglioside monoclonal antibody 3F8. Int J Cancer 82:538–548CrossRefPubMedGoogle Scholar
  3. Boland I, Vassal G, Morizet J, Terrier-Lacombe MJ, Valteau-Couanet D, Kalifa C, Hartmann O, Gouyette A (1999) Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations. Br J Cancer 79:787–792CrossRefPubMedGoogle Scholar
  4. Brignole C, Pagnan G, Marimpietri D, Cosimo E, Allen TM, Ponzoni M, Pastorino F (2003) Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment. Cancer Lett 197:231–235CrossRefPubMedGoogle Scholar
  5. Brodeur GM (2002) Commentary on Kaneko et al.: Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. Int J Pediatr Hematol Oncol 24:608–609CrossRefGoogle Scholar
  6. Burkhart CA, Cheng AJ, Madafiglio J, Kavallaris M, Mili M, Marshall GM, Weiss WA, Khachigian LM, Norris MD, Haber M (2003) Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma. Int J Natl Cancer Inst 95:1394–1403Google Scholar
  7. Castel V, Canete A (2004) A comparison of current neuroblastoma chemotherapeutics. Exp Opin Pharmacother 5:71–80CrossRefGoogle Scholar
  8. Castel V, Canete A, Navarro S, Garcia-Miguel P, Melero C, Acha T, Navajas A, Badal MD (2001) Outcome of high-risk neuroblastoma using a dose intensity approach: improvement in initial but not in long-term results. Med Pediatr Oncol 37:537–542PubMedGoogle Scholar
  9. Cheung NK, Modak S (2002) Oral (1→ 3),(1 →4)-β-D-glucan synergizes with anti-ganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin Cancer Res 8:1217–1223PubMedGoogle Scholar
  10. Cheung NK, Landmeier B, Neely J, Nelson AD, Abramowsky C, Ellery S, Adams RB, Miraldi F (1986) Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2 specific monoclonal antibody against human neuroblastoma xenografted in nude mice. J Natl Cancer Inst 77:739–745PubMedGoogle Scholar
  11. Donfrancesco A, Jenkner A, Castellano A, Ilari I, Milano GM, Sio L, de Cozza R, Fidani P, Deb G, de Laurentis C et al. (2004) Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/ cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age. Acta Paediatr (Suppl) 93:6–11Google Scholar
  12. Evans AE, Kisselbach KD, Yamashiro DJ, Ikegaki N, Camoratto AM, Dionne CA, Brodeur GM (1999) Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts. Clin Cancer Res 36:3594–3602Google Scholar
  13. Evans AE, Kisselbach KD, Liu X, Eggert A, Ikegaki N, Camoratto AM, Dionne C, Brodeur GM (2001) Effect of CEP-751 (KT-6587) on neuroblastoma xenografts expressing TrkB. Med Pediatr Oncol 5:181–184CrossRefGoogle Scholar
  14. Furman WL, Stewart CF, Poquette CA, Pratt CB, Santana VM, Zamboni WC, Bowman LC, Ma MK, Hoffer FA, Meyer WH et al. (1999) Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 171815–1824PubMedGoogle Scholar
  15. Gilbert F, Tsao KL, LaLatta F, Xu L, Potluri VR, LaBadie G (1988) Human neuroblastoma metastases in a nude mouse model: tumor progression and onc gene amplification. Prog Clin Biol Res 271:17–29PubMedGoogle Scholar
  16. Goldsby RE, Matthay KK (2004) Neuroblastoma: evolving therapies for a disease with many faces. Paediatr Drugs 6:107–122PubMedGoogle Scholar
  17. Hackett CS, Hodgson JG, Law ME, Fridlyand J, Osoegawa K, de Jong PJ, Nowak NJ, Pinkel D, Albertson DG, Jain A et al. (2003) Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. Cancer Res 63:5266–5273PubMedGoogle Scholar
  18. Houghton PJ, Stewart CF, Zamboni WC, Thompson J, Luo X, Danks MK, and Houghton JA (1996) Schedule-dependent efficacy of camptothecins in models of human cancer. Ann NY Acad Sci 803:188–201PubMedGoogle Scholar
  19. Houghton PJ, Cheshire PJ, Myers L, Stewart CF, Synold TW, Houghton JA (1992) Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 31:229–239CrossRefPubMedGoogle Scholar
  20. Houghton PJ, Adamson PC, Blaney S, Fine HA, Gorlick R, Haber M, Helman L, Hirschfeld S, Hollingshead MG, Israel MA et al. (2002) Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res 8:3646–3657PubMedGoogle Scholar
  21. Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E, Traxler P (2004) Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 64:2333–2337CrossRefPubMedGoogle Scholar
  22. Imaizumi M, Watanabe A, Kikuta A, Takano T, Ito E, Shimizu T, Tsuchiya S, Iinuma K, Konno T, Ohi R, Hayashi Y (2001) Improved survival of children with advanced neuroblastoma treated by intensified therapy including myeloablative chemotherapy with stem cell transplantation: a retrospective analysis from the Tohoku Neuroblastoma Study Group. Tohoku J Exp Med 195:3–83CrossRefGoogle Scholar
  23. Ishizu H, Bove KE, Ziegler MM, Arya G (1994) Immune-mediated regression of “metastatic” neuroblastoma in the liver. J Pediatr Surg 29:55–160CrossRefGoogle Scholar
  24. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, Kalyandrug S, Christian M, Arbuck S, Hollingshead M, Sausville EA (2001) Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 84:424–431Google Scholar
  25. Joseph JM, Bouquet C, Opolon P, Morizet J, Aubert G, Rossler J, Gross N, Griscelli F, Perricaudet M, Vassal G (2003) High level of stabilized angiostatin mediated by adenovirus delivery does not impair the growth of human neuroblastoma xenografts. Cancer Gene Ther 10:859–866CrossRefPubMedGoogle Scholar
  26. Jouanneau E, Alberti L, Nejjari M, Treilleux I, Vilgrain I, Duc A, Combaret V, Favrot M, Leboulch P, Bachelot T (2001) Lack of antitumor activity of recombinant endostatin in a human neuroblastoma xenograft model. J Neurooncol 51:11–18CrossRefPubMedGoogle Scholar
  27. Kaneko M, Tsuchida Y, Mugishima H, Ohnuma N, Yamamoto K, Kawa K, Iwafuchi M, Sawada T, Suita S (2002) Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol 24:613–621CrossRefPubMedGoogle Scholar
  28. Katsanis E, Bausero MA, Panoskaltsis-Mortari A, Dancisak BB, Xu Z, Orchard PJ, Davis CG, Blazar BR (1996) Irradiation of singly and doubly transduced murine neuroblastoma cells expressing B7-1 and producing interferon-gamma reduces their capacity to induce systemic immunity. Cancer Gene Ther 3:75–82PubMedGoogle Scholar
  29. Katzenstein HM, Rademaker AW, Senger C, Salwen HR, Nguyen NN, Thorner PS, Litsas L, Cohn SL (1999) Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden. Clin Cancer Res 5:4273–4278PubMedGoogle Scholar
  30. Khanna C, Jaboin JJ, Drakos E, Tsokos M, Thiele CJ (2002) Biologically relevant orthotopic neuroblastoma xenograft models: primary adrenal tumor growth and spontaneous distant metastasis. In Vivo 16:77–85PubMedGoogle Scholar
  31. Kim ES, Serur A, Huang J, Manley CA, McCrudden KW, Frischer JS, Soffer SZ, Ring L, New T, Zabski S et al. (2002) Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA 99:11399–11404CrossRefPubMedGoogle Scholar
  32. Kirstein MN, Houghton PJ, Cheshire PJ, Richmond LB, Smith AK, Hanna SK, Stewart CF (2001) Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts. Clin Cancer Res 7:358–366PubMedGoogle Scholar
  33. Kuroiwa M, Ikeda H, Hongo T, Tsuchida Y, Hirato J, Kaneko Y, Suzuki N, Obana K, Makino SI (2001) Effects of recombinant human endostatin on a human neuroblastoma xenograft. Int J Mol Med 8:391–396PubMedGoogle Scholar
  34. Leggas M, Stewart CF, Woo MH, Fouladi M, Cheshire PJ, Peterson JK, Friedman HS, Billups C, Houghton PJ (2002) Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts. Clin Cancer Res 8:3000–3007PubMedGoogle Scholar
  35. Lode HN, Dreier T, Xiang R, Varki NM, Kang AS, Reisfeld RA (1998a) Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma. Proc Natl Acad Sci USA 95:2475–2480CrossRefPubMedGoogle Scholar
  36. Lode HN, Reisfeld RA, Handgretinger R, Nicolaou KC, Gaedicke G, Wrasidlo W (1998b) Targeted therapy with a novel enediyene antibiotic calicheamicin theta(I)1 effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma. Cancer Res 58:2925–2928PubMedGoogle Scholar
  37. Lode HN, Xiang R, Duncan SR, Theofilopoulos AN, Gillies SD, Reisfeld RA (1999) Tumor-targeted IL-2 amplifies T cellmediated immune response induced by gene therapy with single-chain IL-12. Proc Natl Acad Sci USA 96:8591–8596CrossRefPubMedGoogle Scholar
  38. Martinez DA, Kahwash S, O''Dorisio MS, Lloyd TV, McGhee RB Jr, Qualman SJ (1996) Disseminated neuroblastoma in the nude rat. A xenograft model of human malignancy. Cancer 77:409–419CrossRefPubMedGoogle Scholar
  39. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 341: 1165–1173CrossRefPubMedGoogle Scholar
  40. Middlemas DS, Stewart CF, Kirstein MN, Poquette C, Friedman HS, Houghton PJ, Brent TP (2000) Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res 6:998–1007PubMedGoogle Scholar
  41. Pertl U, Wodrich H, Ruehlmann JM, Gillies SD, Lode HN, Reisfeld RA (2003) Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma. Blood 101:649–654CrossRefPubMedGoogle Scholar
  42. Peterson JK, Houghton PJ (2004) Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer 40:837–844CrossRefPubMedGoogle Scholar
  43. Phuangsab A, Lorence RM, Reichard KW, Peeples ME, Walter RJ (2001) Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Lett 172:27–36CrossRefPubMedGoogle Scholar
  44. Raffaghello L, Marimpietri D, Pagnan G, Pastorino F, Cosimo E, Brignole C, Ponzoni M, Montaldo PG (2003) Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse. Cancer Lett 197:205–209CrossRefPubMedGoogle Scholar
  45. Redlinger RE Jr, Mailliard RB, Lotze MT, Barksdale EM Jr (2003a) Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo. J Pediatr Surg 38:301–307CrossRefPubMedGoogle Scholar
  46. Redlinger RE Jr, Shimizu T, Remy T, Alber S, Watkins SC, Barksdale EM Jr (2003b) Cellular mechanisms of interleukin-12-mediated neuroblastoma regression. J Pediatr Surg 38:199–204CrossRefPubMedGoogle Scholar
  47. Ribatti D, Raffaghello L, Pastorino F, Nico B, Brignole C, Vacca A, Ponzoni M (2002) In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression. Int J Cancer 102:351–354CrossRefPubMedGoogle Scholar
  48. Santana VM, Zamboni WC, Kirstein MN, Tan M, Liu T, Gajjar A, Houghton PJ, Stewart CF (2003) A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin Cancer Res 9:633–640PubMedGoogle Scholar
  49. Shusterman S, Grupp SA, Maris JM (2000) Inhibition of tumor growth in a human neuroblastoma xenograft model with TNP-470. Med Pediatr Oncol 35:673–676CrossRefPubMedGoogle Scholar
  50. Shusterman S, Grupp SA, Barr R, Carpentieri D, Zhao H, Maris JM (2001) The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. Clin Cancer Res 7:977–984PubMedGoogle Scholar
  51. Siapati KE, Barker S, Kinnon C, Michalski A, Anderson R, Brickell P, Thrasher AJ, Hart SL (2003) Improved antitumour immunity in murine neuroblastoma using a combination of IL-2 and IL-12. Br J Cancer 88:1641–1648CrossRefPubMedGoogle Scholar
  52. Soto LJ III, Sorenson BS, Nelson BW, Solis SJ, Leonard AS, Saltzman DA (eds) (2004) Preferential proliferation of attenuated Salmonella typhimurium within neuroblastoma. J Pediatr Surg 39:937–940Google Scholar
  53. Stewart CF, Leggas M, Schuetz JD, Panetta JC, Cheshire PJ, Peterson J, Daw N, Jenkins JJ III, Gilbertson R, Germain GS, Harwood FC, Houghton PJ (2004) Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res 64:7491–7499CrossRefPubMedGoogle Scholar
  54. Thompson J, Zamboni WC, Cheshire PJ, Lutz L, Luo X, Li Y, Houghton JA, Stewart CF, Houghton PJ (1997) Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin Cancer Res 3:423–431PubMedGoogle Scholar
  55. Thompson J, Guichard SM, Cheshire PJ, Richmond LB, Poquette CA, Ragsdale ST, Webber B, Lorsbach R, Danks MK, Houghton PJ (2001) Development, characterization and therapy of a disseminated model of childhood neuroblastoma in SCID mice. Cancer Chemother Pharmacol 47:211–221CrossRefPubMedGoogle Scholar
  56. Tsuchida Y, Yokomori K, Iwanaka T, Saito S (1984) Nude mouse xenograft study for treatment of neuroblastoma: effects of chemotherapeutic agents and surgery on tumor growth and cell kinetics. J Pediatr Surg 19:72–76PubMedGoogle Scholar
  57. Tsuchida Y, Shitara T, Kuroiwa M, Ikeda H (2003) Current treatment and future directions in neuroblastoma. Indian J Pediatr 70:809–812PubMedGoogle Scholar
  58. Turner WJ, Chatten J, Lampson LA (1990) Human neuroblastoma cell growth in xenogeneic hosts: comparison of T cell-deficient and NK-deficient hosts, and subcutaneous or intravenous injection routes. J Neurooncol 8:121–132CrossRefPubMedGoogle Scholar
  59. Valteau-Couanet D, Benhamou E, Vassal G, Stambouli F, Lapierre V, Couanet D, Lumbroso J, Hartmann O (2000) Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma. Bone Marrow Transplant 25:937–942CrossRefPubMedGoogle Scholar
  60. Vertuani S, de Geer A, Levitsky V, Kogner P, Kiessling R, Levitskaya J (2003) Retinoids act as multistep modulators of the major histocompatibility class I presentation pathway and sensitize neuroblastomas to cytotoxic lymphocytes. Cancer Res 63:8006–8013PubMedGoogle Scholar
  61. Wagner LM, Guichard SM, Burger RA, Morton CL, Straign CM, Ashmun RA, Harris LC, Houghton PJ, Potter PM, Danks MK (2002) Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: preclinical assessment and application to bone marrow samples from neuroblastoma patients. Cancer Res 62:5001–5007PubMedGoogle Scholar
  62. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM (1997) Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 16:2985–2995CrossRefPubMedGoogle Scholar
  63. Weiss WA, Godfrey T, Francisco C, Bishop JM (2000) Genomewide screen for allelic imbalance in a mouse model for neuroblastoma. Cancer Res 60:2483–2487PubMedGoogle Scholar
  64. Wierdl M, Wall A, Morton CL, Sampath J, Danks MK, Schuetz JD, Potter PM (2003) Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance. Mol Pharmacol 64:279–288CrossRefPubMedGoogle Scholar
  65. Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, Park JW (2003). YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 95:516–525PubMedGoogle Scholar
  66. Zamboni WC, Stewart CF, Thompson J, Santana VM, Cheshire PJ, Richmond LB, Luo X, Poquette C, Houghton JA, Houghton PJ (1998) Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst 90:505–511CrossRefPubMedGoogle Scholar
  67. Ziegler MM, Ishizu H, Nagabuchi E, Takada N, Arya G (1997) A comparative review of the immunobiology of murine neuroblastoma and human neuroblastoma. Cancer 79:1757–1766CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Jennifer K. Peterson
  • Peter J. Houghton

There are no affiliations available

Personalised recommendations